Abortion Bans Are Likely to Restrict Care for MS Patients: Researchers
Note: This story was updated on July 25, 2022, for the headline to reflect researchers gave this information in a…
Articles by Marisa Wexler, MS
Natalizumab, Tysabri Biosimilar, Up for Approval in Europe
The European Medicines Agency (EMA) has agreed to review a request to approve Polpharma Biologics‘ biosimilar natalizumab for the…
Certain MS Lesions Linked to Worse Disability, but Location Not a Factor
The presence of iron rim lesions (IRLs), which are regions of chronic nervous system damage with ongoing inflammation, visible on MRI…
Rituximab Outperforms Tecfidera at Preventing Relapses in Phase 3 Trial
Multiple sclerosis (MS) patients treated with rituximab were more than five times less likely to experience a relapse…
EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead
An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned…
Women with MS More Likely to Be Sexually, Emotionally Abused
Rates of sexual and emotional abuse are higher in women with multiple sclerosis (MS) compared with women in the…
Aubagio May Significantly Lower Relapse Risk in Children With MS
Treatment with Aubagio (teriflunomide) may significantly reduce the risk of relapse in children with multiple sclerosis (MS), according…
Early MS Symptoms May Help Predict Diagnosis, Disease Course
Some prodromal symptoms of multiple sclerosis (MS) — symptoms that are evident before the disease begins in earnest…
Levels of Certain Inflammatory Proteins May Predict Risk of Relapse
Levels of certain inflammatory proteins in the cerebrospinal fluid, the liquid around the brain and spinal cord, may help predict…
Researchers Distinguish Remyelinated Brain Lesions Via MRI
An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with…
Efficacy, Safety of Mavenclad in Real World Similar to That of Trials
The safety and efficacy of the approved multiple sclerosis (MS)Â therapy Mavenclad (cladribine) in a real-world group…
Long-term Zeposia May Help Cognitive Function in Patients, Data Show
Long-term treatment with Zeposia (ozanimod) stabilizes or even improves cognitive function in adults with relapsing forms of multiple…
No Disease Activity After 4 Years for Nearly 80% of Patients on Kesimpta
People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four…
Proteins Called Tenascins Found to Block Myelin Repair in Mouse Model
Proteins called tenascins block the regeneration of myelin by modulating the activity of oligodendrocytes, myelin-making cells of the central nervous…
T-cells in Bone Marrow Work to Drive Inflammatory MS Attacks
Unusual growth in an immune cell class called myeloid cells is evident in the bone marrow of people with multiple sclerosis…
Neural Sleeve Improves Mobility, Reduces Pain and Depression: Cionic
Cionic‘s leg-worn Neural Sleeve, recently authorized in the U.S. to aid walking in people with multiple sclerosis (MS)…
Vidofludimus Calcium Safely Reduced RRMS Brain Lesions
Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple…
2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment
Treatment with foralumab nasal spray resulted in marked clinical improvements after three months in the second secondary progressive multiple…
MS Tied to 75% Increased Risk of Mortality in US Study
The overall risk of death is about 75% higher for people with multiple sclerosis (MS) than in the general…
Cancer Therapy Topotecan Could Be Repurposed to Treat MS: Study
A medication currently approved to treat certain kinds of cancer, called topotecan, could be repurposed for treating neuroinflammatory conditions such…
No Disease Activity for 58% of Those on Aubagio After 2 Years: Study
More than half of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease…
FDA Decision on Ublituximab for Relapsing MS Pushed to Year’s End
The U.S. Food and Drug Administration (FDA) is extending by three months its review of ublituximab, an experimental anti-CD20 antibody…
New Scale May Better Assess MS Changes, Therapy Response in Mice
A new scoring system might more precisely evaluate disease development, severity, and treatment response in a commonly used mouse model…
BBB Leakiness Decrease May Predict Effectiveness of Lemtrada Treatment
Among multiple sclerosis (MS) patients starting on Lemtrada (alemtuzumab), an early decrease in the leakiness of the blood-brain…
Ponvory Reduces Risk of Worsening Disability Over Placebo
Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms…
Lesions in 3 Brain Regions Can Help Distinguish MS From Like Disorders
People with multiple sclerosis (MS) are more likely to have lesions in three regions of the brain — the…
Preclinical Data Support Remyelinating Potential of ABX-002
ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the…
Marriage, Education, DMT Affect Patients’ Treatment Adherence
Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely…
‘Hidden’ Disabilities Fairly Common at RRMS Diagnosis, Study Finds
Many people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study…
With Rituximab, B-cell Counts Predict COVID-19 Vaccine Response
Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a…